Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

So, while you should always follow the fundamentals of healthy living – like exercising and eating a balanced diet – ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE: ABT) with an "overweight" rating and a price target of $131 ...

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

Abbott’s FreeStyle Libre devices involve a small sensor applied ... Abbott’s industry partners seem to view these collaborations in the same way. Que Dallara, president of Medtronic Diabetes ...

Designed to track glucose in real time, Lingo is based on Abbott's FreeStyle Libre CGM technology ... It is also accessible in the UK. Per a Grand View Research report, the global CGM devices ...

led by FreeStyle Libre. The nutritional segment is benefiting from market share gains for its baby formula products. Abbott expects its total 2024 revenue to rise 9.5% to 10% on an organic basis.